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NEW FINDINGS 
What is the central question of this study? 
Glucagon-like peptide-1 (GLP-1) is an important obesity/diabetes target, with effects 
dependent on circulating GLP-1 concentrations. Peripheral tissues extract GLP-1, 
therefore sampling venous versus arterialised blood may provide different GLP-1 
concentrations. This study examined whether arterialisation alters GLP-1 
concentrations during fasting and feeding. 
What is the main finding and its importance? 
This study demonstrates that venous blood provides lower postprandial, but not 
fasting, GLP-1 concentrations versus arterialised blood. Therefore, when accurate 
assessment of postprandial peripheral availability of GLP-1 is required, blood 
sampling methods should be carefully considered, clearly reported, and 
arterialisation is recommended. 
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ABSTRACT 1 
Glucagon-like peptide-1 (GLP-1) displays concentration-dependent effects on 2 
metabolism, appetite and angiogenesis, so accurate determination of circulating 3 
GLP-1 concentrations is important. This study compared GLP-1 concentrations in 4 
venous versus arterialised blood under both fasted and fed conditions. Venous and 5 
arterialised blood samples were simultaneously drawn from ten, young, healthy men 6 
before, and 30, 60 and 120 min after, ingestion of 75 g glucose. Plasma GLP-1 7 
concentrations increased in response to glucose ingestion (time effect: p < 0.01) and 8 
to a lesser extend in venous versus arterialised plasma (time x arterialisation 9 
interaction: p < 0.01). Accordingly, the plasma incremental area under the curve was 10 
lower in venous versus arterialised plasma (974 ± 88 versus 1214 ± 115 pmol·L x 11 
120 min-1, respectively, p = 0.049). In the postprandial state, there was a positive 12 
relationship between arterialised GLP-1 concentrations and the venous-arterialised 13 
difference in GLP-1 concentrations (r2 = 0.51; p < 0.01). Both arterialised and venous 14 
peak GLP-1 concentrations showed positive relationships with peak arterialised 15 
insulin concentrations (both r2 > 0.6, p < 0.01). Venous sampling results in lower 16 
concentrations of GLP-1 in the postprandial, but not the fasted state compared to 17 
arterialised blood. This absolute difference is biologically meaningful and is 18 
magnified when GLP-1 availability is high. Therefore, sampling from arterialised 19 
blood may provide a better chance of detecting small differences in postprandial 20 
GLP-1 availability with interventions and if absolute GLP-1 concentrations are of 21 
interest, the blood sampling method should be carefully considered and clearly 22 
reported. 23 
 24 
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INTRODUCTION 34 
 35 
Postprandial glucagon-like peptide-1 (GLP-1) concentrations appear to 36 
mediate many of the beneficial changes in metabolism and feeding behaviour 37 
following bariatric surgery (Drucker, 2018). Consequently, GLP-1 is a major target in 38 
diabetes research (Drucker, 2018) and various nutritional, pharmacological and 39 
surgical methods are explored with the intention to elevate circulating GLP-1 40 
availability and/or action (Edwards et al., 2001; Gonzalez et al., 2013; Nauck et al., 41 
2017; Jirapinyo et al., 2018). Whilst much of the evidence supporting mechanistic 42 
roles of GLP-1 involve exogenous agonists or DPP-IV inhibitors, there is also 43 
evidence that endogenous GLP-1 regulates insulin secretion and appetite via studies 44 
using GLP-1 receptor antagonists or physiological infusions (Aulinger et al., 2014; 45 
Tan et al., 2017). Given that effects of GLP-1 are concentration-dependent (Nauck et 46 
al., 1993; Verdich et al., 2001; Aronis et al., 2013; Gonzalez & Stevenson, 2014; 47 
Gonzalez et al., 2015), accurate determination of peripheral exposure to GLP-1 is 48 
especially important.  49 
 In the fasted state, arterio-venous differences in GLP-1 concentrations across 50 
the leg are have been reported during intravenous GLP-1 infusion (Asmar et al., 51 
2017). Venous sampling, therefore, may not accurately determine tissue exposure to 52 
GLP-1. Since GLP-1 is the major incretin hormone (Holst, 2007; Drucker, 2018), 53 
these arterio-venous differences could alter inferences regarding the relationship 54 
between postprandial GLP-1 and insulinaemia. Moreover, if differences between 55 
venous and arterialised blood are not consistent, then comparisons between studies 56 
using different blood sampling methods would be problematic. Indeed, blood 57 
sampling methods for GLP-1 measurement commonly vary between studies, which 58 
may sample from capillaries, arterial, arterialised or venous blood (Gonzalez & 59 
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Stevenson, 2014; Green et al., 2014; Gonzalez et al., 2015; Asmar et al., 2017), 60 
albeit arterial blood is much less frequently sampled due being more technically 61 
challenging. However, to date, no study has ever examined whether postprandial 62 
GLP-1 concentrations differ in venous compared to arterialised blood, and thus 63 
whether the method of blood sampling has implications for determining the 64 
relationship between GLP-1 and insulinemia (i.e. the incretin effect). 65 
The primary aim of the present study was to assess whether venous blood 66 
exhibits concentrations of GLP-1 that are representative of arterialised blood, with a 67 
secondary aim to consider whether any apparent discrepancy affects the expected 68 
relationship between postprandial GLP-1 and insulinaemia. We hypothesised that 69 
postprandial GLP-1 concentrations would be lower in venous compared to 70 
arterialised blood and that this would alter the relationship between GLP-1 and 71 
insulinaemia. 72 
 73 
 74 
METHODS 75 
Ethical approval 76 
The data presented in this study include plasma samples collected as part of 77 
a wider study (registered on clinicaltrials.gov as NCT02852044) but all data reported 78 
here are novel and have not been previously published, other than the participant 79 
characteristics and mean insulin concentrations (Edinburgh et al., 2017). The study 80 
protocols adhered to the second Declaration of Helsinki and were approved by the 81 
University of Bath Research Ethics Approval Committee for Health (ref: EP 15/16 82 
44). All participants provided informed written consent prior to participating.  83 
 84 
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Participants and study design 85 
Ten young, healthy men (mean ± SD; age: 23 ± 3 years; body mass index: 23.3 ± 86 
1.8 kg·m2) undertook a 75-g oral glucose tolerance test (OGTT) after an hour of rest 87 
with blood sampled from each arm, comprising one arterialised and one non-88 
arterialised vein, simultaneously (Edinburgh et al., 2017). Inclusion criteria included: 89 
aged 18 to 49 years, healthy, males. Exclusion criteria included: diagnosis of any 90 
bleeding disorder or taking medication which impacts blood coagulation, diagnosis of 91 
metabolic disease, or any other contraindications to the procedures in the present 92 
study.  93 
 94 
Oral glucose tolerance test, blood sampling and analysis 95 
After a 10-h overnight fast and 24 h of dietary and physical activity control, 96 
participants arrived in the laboratory at 08:00 ± 01:00 h. Height was measured to the 97 
nearest 0.1 cm with a stadiometer (Seca Ltd, Birmingham, UK), with participants 98 
barefoot in the Frankfurt plane. Body mass was measured in light clothing, to the 99 
nearest 0.1 kg using electronic weighing scales (BC543 Monitor, Tanita, Tokyo, 100 
Japan). Participants placed their dominant hand into a heated-air box with the 101 
temperature set at 55ºC (Mass Spectrometry Facility; The University of Vermont & 102 
the University of Vermont Medical Center). Following a 20-min acclimation period, an 103 
intravenous catheter was inserted – retrograde – into a dorsal hand vein of the 104 
heated hand for sampling of arterialised blood. A second catheter was inserted – 105 
antegrade – into a vein in the antecubital fossa of the contralateral arm for sampling 106 
of venous blood. A baseline blood sample was drawn simultaneously from both 107 
arterialised and non-arterialised veins by two members of the research team and 108 
dispensed into EDTA-coated tubes (BD, Oxford, UK) before centrifugation 4°C and 109 
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3500 g) for 10-min (Heraeus Biofuge Primo R, Kendro Laboratory Products Plc., UK) 110 
to obtain plasma. DPP4 inhibitors were not added to the sample collection tubes 111 
since the aim of this study was to assess total GLP-1 concentrations, rather than 112 
GLP-17-36. Participants then rested for 60 min in a semi-supine position, before 113 
consuming 75 g glucose dissolved in 300 mL water. During the postprandial period, 114 
participants remained at rest in a semi-supine position with no further food intake. 115 
Water intake was permitted ad libitum on the first trial, and was replicated on the 116 
second trial. Blood samples were analysed for GLP-1 and insulin concentrations at 117 
baseline, immediately prior to the OGTT, and at 30, 60 and 120 min post-OGTT. 118 
GLP-1 and insulin concentrations were determined by ELISA (Merck Millipore, 119 
Watford, UK and Mercodia AB, Uppsala, Sweden, respectively; intra-assay CV both 120 
<7%). The antibodies in the GLP-1 assay employed are specific to both GLP-17-36 121 
and GLP-19-36 and thus this assay captures total GLP-1 concentrations. Furthermore, 122 
the recovery is 90-110% and there is no significant cross-reactivity with GLP-2, GIP, 123 
glucagon or oxyntomodulin (Bak et al., 2014). The intra-assay and inter-assay 124 
coefficients of variation are <5% and <12%, respectively. 125 
 126 
Statistical analysis 127 
Statistical analyses were performed in GraphPad Prism (Version 7, GraphPad 128 
Software, San Diego, USA) and SPSS (Version 24, IBM SPSS Statistics, Armonk, 129 
NY, USA). Data are presented as means ± SD in text, whereas error bars on figures 130 
are 95% confidence intervals normalized to remove between subject variance for 131 
within-subject designs (Loftus & Masson, 1994). The area under the curve (AUC) 132 
and incremental area under the curve (iAUC) were calculated using the trapezoidal 133 
rule. The Matsuda insulin sensitivity index (ISIMatsuda) was calculated as previously 134 
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described (Matsuda & DeFronzo, 1999; Edinburgh et al., 2017). Prior to statistical 135 
analyses, residuals of comparisons were checked for normality using the Shapiro-136 
Wilk test in addition to visual inspection of histograms. There were no clear 137 
indications of non-normal distribution and therefore parametric statistics were 138 
employed for all variables.  Plasma GLP-1 concentrations were assessed by a two-139 
way (time x arterialisation) repeated measures ANOVA. Where an interaction effect 140 
was present, post-hoc comparisons were adjusted for multiple comparisons using 141 
the Bonferroni correction. Fasting values represent the average of time points -60 142 
min and 0 min. Pearson correlations were employed to determine the relationships 143 
between venous-arterialised differences and the absolute GLP-1 concentration, and 144 
between peak GLP-1 concentrations (from each vein) and peak insulinaemia. 145 
Differences in the AUC and iAUC between venous versus arterialised blood 146 
samples, were assessed by paired t-tests. A p value of ≤0.05 was considered 147 
statistically significant. 148 
 149 
 150 
RESULTS 151 
Venous-arterialised differences in GLP-1 concentrations 152 
After glucose ingestion, plasma GLP-1 concentrations increased (time effect: p < 153 
0.01), and to a lesser extent in venous versus arterialised plasma (time x 154 
arterialisation interaction: p < 0.01; Figure 1A), which was most clear at peak GLP-1 155 
concentrations. This resulted in a plasma AUC and iAUC that were both lower in 156 
venous versus arterialised plasma (Figures 1B and 1C, respectively). 157 
 158 
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An interaction effect of blood sampling method (venous versus arterialised) and 159 
feeding status (fasted vs peak postprandial) on plasma GLP-1 concentrations was 160 
detected (p = 0.026), whereby plasma GLP-1 concentrations did not differ between 161 
venous and arterialised blood samples in the fasted state (average of -60 and 0 min; 162 
mean difference: -1.52 pmol·L-1; 95%CI: -5.30 to 2.27 pmol·L-1; Figure 1D). 163 
However, in the postprandial state, peak plasma GLP-1 concentrations were lower in 164 
venous versus arterialised samples (-6.81 pmol·L-1; 95%CI: -10.60 to -3.03 pmol·L-1; 165 
Figure 1D).  166 
  167 
 168 
 169 
 170 
 171 
 172 
 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
Figure 1. (A) Plasma glucagon-like peptide-1 (GLP-1) concentrations, (B) total area 
under the curve (AUC), and (C) incremental area under the curve (iAUC) determined in 
arterialised and non-arterialised venous blood before and during an oral glucose 
tolerance test (OGTT). (D) Interaction effect of blood sampling method (venous versus 
arterialised) and feeding status (fasted versus peak postprandial) on plasma GLP-1 
concentrations during oral glucose tolerance test. Data are means ± n95%CI; n = 10. 
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 184 
 185 
Relationships between variables 186 
Peak arterialised GLP-1 concentrations demonstrated a strong negative correlation 187 
with the venous arterialised difference in peak GLP-1 concentrations (r2 = 0.85; p < 188 
0.001; Figure 2A). However, the relationship between ISIMatsuda and the venous-189 
arterialised difference in GLP-1 AUC was weak (r2 = 0.03; p = 0.62). 190 
 191 
Postprandial peak GLP-1 concentrations determined in arterialised plasma displayed 192 
a strong relationship with postprandial peak arterialised insulin concentrations 193 
(Figure 2B; r2 = 0.64, p < 0.01). Similarly, postprandial peak GLP-1 concentrations 194 
determined in venous plasma also displayed a strong relationship with postprandial 195 
peak arterialised insulin concentrations (Figure 2B; r2 = 0.62, p < 0.01). 196 
Furthermore, there was no evidence that the relationships between postprandial 197 
GLP-1 and insulinaemia differed depending on the blood sampling method when 198 
GLP-1 and insulin concentrations were expressed as the AUC (venous: r2 = 0.13, p 199 
= 0.31; arterialised: r2 = 0.12, p = 0.32) or the iAUC (venous: r2 = 0.16, p = 0.26; 200 
arterialised: r2 = 0.18, p = 0.22). 201 
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Figure 2.  (A) Relationship between peak plasma glucagon-like peptide-1 (GLP-1) 
concentrations determined in arterialised blood and the venous-arterialised 
difference in peak plasma GLP-1 concentrations. (B) Relationship between 
plasma GLP-1 concentrations determined in arterialised or venous blood and 
peak arterialised insulin concentrations during an oral glucose tolerance test 
(OGTT). Data are individual data points and shaded areas are means ± 95%CI; n 
= 10. 
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DISCUSSION 224 
The present study provides the first evidence that venous plasma provides 225 
lower postprandial, but not fasting, GLP-1 concentrations compared to arterialised 226 
plasma, with the absolute magnitude of these differences amplified at higher GLP-1 227 
concentrations. Therefore, future studies should carefully consider the sample 228 
method for determination of GLP-1 availability. The difference in GLP-1 229 
concentrations between arterialised and non-arterialised blood samples does not, 230 
however, appear to have implications for determining the relationship between GLP-231 
1 availability and postprandial insulinaemia. 232 
Determination of the circulating concentrations of GLP-1 is essential for 233 
appropriate inferences regarding peripheral actions of GLP-1. GLP-1 displays 234 
concentration-dependent effects on satiety (Verdich et al., 2001), glucose-induced 235 
insulin secretion (Nauck et al., 1993) and angiogenesis (Aronis et al., 2013). The 236 
difference in measured GLP-1 concentrations between venous and arterialised 237 
plasma in the present data ranged from -20 to 7 pmol·L-1. These differences are 238 
biologically meaningful, as they are greater than the biological and technical variation 239 
(~5.3 and ~3.8 pmol·L-1, respectively; unpublished observations), and equate to 240 
more than 10 units on a typical visual analogue scale for hunger, satiety or appetite 241 
(Verdich et al., 2001). Therefore, interpretations drawn from studies reporting effects 242 
on GLP-1 availability should be made with careful consideration of the blood 243 
sampling method in mind.  244 
GLP-1 exists in at least two forms in humans, with GLP-17-36 known as the 245 
primary activator of the classical GLP-1 receptor. We chose to assess total GLP-1 246 
rather than GLP-17-36 concentrations for two reasons: first, total GLP-1 247 
concentrations are the best indication of GLP-1 secretion in humans in vivo (Holst, 248 
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2007); second, to rule-out changes in GLP-1 concentrations due to activity of 249 
dipeptidyl peptidase IV (DPPIV) across tissue beds. In humans, GLP-1 is almost 250 
entirely secreted as GLP-17-36 by the enteroendocrine cells of the intestine (Orskov 251 
et al., 1994; Holst, 2007). GLP-17-36 is subsequently cleaved by DPPIV which acts on 252 
GLP-17-36 in the endothelium, liver and circulating plasma (Holst, 2007). 253 
Furthermore, DPPIV is secreted by adipose tissue (Lamers et al., 2011; Sell et al., 254 
2013), therefore venous-arterialised differences in GLP-17-36 could merely represent 255 
DPPIV action. By detecting changes in total GLP-1 concentrations between 256 
arterialised and venous blood, we can rule out DPPIV as a mechanism for this 257 
response. Consequently, our data suggest that differences in GLP-1 concentrations 258 
between arterialised and venous blood are likely due to uptake/entrapment in 259 
peripheral tissues in the postprandial state. 260 
Peripheral tissue extraction of GLP-1 in the postprandial state could be 261 
increased due to either a direct increase in cellular uptake of GLP-1 and/or increased 262 
tissue perfusion. The insulin response to feeding stimulates microvascular 263 
recruitment and increases tissue perfusion (Vincent et al., 2002). This may explain 264 
why we observed a greater venous-arterialised difference in GLP-1 in the 265 
postprandial state. We also found a positive correlation between the venous-266 
arterialised difference in GLP-1 and GLP-1 availability, but did not observe any 267 
meaningful relationship between an index of insulin sensitivity and the venous-268 
arterialised difference in GLP-1. Therefore, peripheral GLP-1 extraction could be due 269 
to increased tissue perfusion and/or increased GLP-1 availability, but at present, 270 
seems not to be related to insulin sensitivity. 271 
One of the primary actions of GLP-1 is to potentiate glucose-induced insulin 272 
secretion (Holst, 2007; Drucker, 2018), i.e., the incretin effect. In order to assess 273 
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whether arterialisation of the veins has implications for inferences of the incretin 274 
effect, we assessed the relationship between peak arterialised insulin concentrations 275 
and GLP-1 concentrations determined in arterialised or venous plasma. Both 276 
arterialised and venous peak GLP-1 concentrations strongly and positively correlated 277 
with peak arterialised insulin concentrations (both displaying an r2 > 0.6). This 278 
suggests that both GLP-1 and insulin are removed from arterial blood at a similar 279 
rate, and thus, arterialisation does not appear to influence the interpretation of the 280 
incretin effect. Whether this relationship holds under differing populations, remains to 281 
be seen.  282 
The present study was limited by the small sample size (which can 283 
overestimate effect sizes) and the relatively homogenous cohort of males. Therefore, 284 
further work in larger cohorts with females, and individuals differing in weight status 285 
will be useful to make these data more generalisable. There is little physiological 286 
rationale to expect that other human cohorts would differ in the direction of venous-287 
arterialised difference observed in the present study, however the magnitude of this 288 
venous arterialised difference could be altered in other cohorts. 289 
To conclude, venous blood provides lower GLP-1 concentrations than 290 
arterialised blood in the postprandial, but not the fasted state. This difference is 291 
biologically meaningful and is magnified under conditions when GLP-1 availability is 292 
elevated. Therefore, comparison of findings from studies using venous and 293 
arterialised blood samples should be performed with care, and sampling from 294 
arterialised blood may provide a better chance of detecting small differences in 295 
postprandial GLP-1 availability with interventions. However, the relationship between 296 
GLP-1 and insulinaemia does not appear to depend on whether blood samples are 297 
arterialised. Thus, if absolute GLP-1 concentrations are of interest, it should be 298 
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carefully considered and reported whether samples are drawn from an artery, 299 
arterialised-vein or vein. 300 
 301 
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